Skip to content
value.today
Rhythm METabolic, Inc. logo

Rhythm METabolic, Inc.

Total raised
$60 M
2 rounds on record
Latest round
$20 M
Jan 2017
First round on record
Aug 2015
Today
Went public
See the company page

Rhythm METabolic, Inc. is listed today as Rhythm Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Rhythm METabolic, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2017$20 MNo. 2$10 to $50 million

Rhythm METabolic, Inc.: Raise no. 2, Jan 2017

Investors in this round

14 investors had bought by the notice of Jan 20, 2017: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Rhythm METabolic, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $41 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series A Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bart T. Henderson · Executive Officer, Promoter · Mr. Henderson is the President and Treasurer of the Issuer.
  • Keith Gottesdiener · Executive Officer, Director, Promoter · Mr. Gottesdiener is the Chief Executive Officer of the Issuer.
  • Christophe Jean · Director
  • David J. McGirr · Director
  • David P. Meeker, M.D. · Director
  • Edward T. Mathers · Director
  • Jonathan T. Silverstein · Director
  • Neil Exter · Director
  • Todd T. Foley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Bart Henderson, President of the Issuer. Source: SEC Form D, newest notice filed Jan 20, 2017. Read the notice at the SEC.

equitySEC
Aug 2015$40 MNo. 1$10 to $50 million

Rhythm METabolic, Inc.: Raise no. 1, Aug 2015

Investors in this round

12 investors had bought by the notice of Dec 10, 2015: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Rhythm METabolic, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series A Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bart T. Henderson · Executive Officer · Mr. Henderson is the President and Treasurer of the Issuer.
  • Keith Gottesdiener · Executive Officer, Director · Mr. Gottesdiener is the Chief Executive Office of the Issuer.
  • Christophe Jean · Director
  • David J. McGirr · Director
  • David P. Meeker, M.D. · Director
  • Edward T. Mathers · Director
  • Jonathan T. Silverstein · Director
  • Neil Exter · Director
  • Todd T. Foley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Bart Henderson, President of the Issuer. Source: SEC Form D and 1 amendment, newest notice filed Dec 10, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Rhythm Pharmaceuticals, Inc., its revenue in fiscal 2025 came from these business segments: Single reportable segment $189.76 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Rhythm METabolic, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2017).

    SEC Form D · Jan 2017

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2017

Products and services#

No products or services of Rhythm METabolic, Inc. are on record.

Investors#

24 named in official filings. Open an investor to see everything it has backed.

Investors in Rhythm METabolic, Inc.
InvestorKindAmountRoundRoleSource
Baker Bros. Advisors (GP) LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Baker Bros. Advisors LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
David P. MeekerPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2017)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Deerfield Mgmt III, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Deerfield Private Design Fund III, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Hadley Harbor Master Investors (Cayman) L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Ipsen, S.A.Companynot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Keith Michael GottesdienerPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2017)SEC Form 3
MPM Asset Management Investors BV5 LLCFund or asset managernot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
MPM Bioventures V GP LLCVenture capitalnot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
MPM Bioventures V LLCVenture capitalnot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
MPM Bioventures V, L.P.Venture capitalnot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
NEA 13 GP, LtdCompanynot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
NEA Partners 13, Limited PartnershipFund or asset managernot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
New Enterprise Associates 13 LPFund or asset managernot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
OrbiMed Capital GP V LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Pfizer IncFund or asset managernot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Third Rock Ventures GP, L.P.Venture capitalnot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Third Rock Ventures LPVenture capitalnot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
TRV GP, LLCOthernot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 14 investors.

Largest shareholders today

Institutions holding Rhythm Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Rhythm METabolic, Inc.
NameRoleNamed in
Bart T. HendersonMr. Henderson is the President and Treasurer of the Issuer.Jan 2017
Keith GottesdienerMr. Gottesdiener is the Chief Executive Officer of the Issuer.Jan 2017
Christophe JeanDirectorJan 2017
David J. McGirrDirectorJan 2017
David P. Meeker, M.D.DirectorJan 2017
Edward T. MathersDirectorJan 2017
Jonathan T. SilversteinDirectorJan 2017
Keith GottesdienerMr. Gottesdiener is the Chief Executive Officer of the Issuer.Jan 2017
Neil ExterDirectorJan 2017
Todd T. FoleyDirectorJan 2017
Jean ChristopheDirectorAug 2015
Bart T. HendersonMr. Henderson is the President and Treasurer of the Issuer.Jan 2017
Keith GottesdienerMr. Gottesdiener is the Chief Executive Officer of the Issuer.Jan 2017

About

Company in Boston, United States.

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.